The Contour Collection is no longer just about the eyes. Dr. Diamond’s Metacine is expanding its targeted treatment lineup with LipLift, a $120 topical serum launching Tuesday, marking the second product in the collection following April’s EyeLift Bioremodeling Peptide Multiplex. The move signals a deeper play into the anti-aging lip category, where the brand’s founder, celebrity plastic surgeon Jason Diamond, says he has seen every lip problem the face has to offer. Main Developments LipLift is built around the brand’s proprietary Hyaluron Peptide-6 BioFill, a topical volumizing technology that combines six advanced biomimetic peptides, hyaluronic acid oil, poly-hyaluronic acid filling spheres, and bioidentical skin lipids. The formula targets volume loss, reduced definition, dryness, vertical lip lines, and a less distinct vermilion border—all signs of aging that stem from declining collagen, hyaluronic acid, and supportive adipose tissue. Clinical data from an independent third-party study of 33 participants showed that 100 percent saw improvement across seven key signs of lip aging after a single use, while 96 percent reported enhanced lip volume after four weeks. These results echo the momentum of EyeLift, which has already become the brand’s number-two selling SKU, trailing only the InstaFacial Plasma Bioactive Growth Factor Serum, $200, according to cofounder and CEO Dr. Jessica Combs. Read also: AI Search Dominance: Top 5 Hair Care Brands Claim Half of Visibility EyeLift now represents approximately 20 percent of company revenue year-to-date, a figure Combs attributes to strong consumer response to the Contour Collection’s proposition and messaging. The brand, however, declined to provide sales forecasts for LipLift, though industry sources estimate it could generate $5 million to $7 million in omnichannel sales in its first year. Background Dr. Diamond, known for his surgical and nonsurgical expertise, developed the Contour Collection to address facial aging comprehensively. He explained that his goal was to create products that encompass most of the issues he sees in practice, offering solutions to people who cannot visit him in person. The collection’s first launch, EyeLift, debuted in April and quickly gained traction, reinforcing the brand’s positioning in the bioremodeling peptide space. The brand’s existing retail footprint includes Nordstrom, Bluemercury, Violet Grey, Goop, Bloomingdales, Dermstore.com, Fwrd, Revolve, and Moda Operandi. With LipLift, the company is also expanding its physical presence, entering seven Bloomingdale’s stores via Beautyspace after being previously online-only at that retailer. Why It Matters Lips are among the first facial areas to show aging, yet the category remains underserved by topical solutions that address multiple causes simultaneously. LipLift’s clinical claims—particularly the 100 percent improvement after one use—position it as a potential game-changer in a market where consumers increasingly seek noninvasive alternatives to injectables. The rapid success of EyeLift, which became a top seller within months, suggests the Contour Collection is resonating with a demographic that values science-backed, at-home treatments. For Dr. Diamond’s Metacine, the expansion also diversifies revenue beyond its hero Plasma serum, reducing reliance on a single product. The move into retail stores via Bloomingdale’s Beautyspace indicates a strategic push to capture omnichannel shoppers who prefer in-person experiences, potentially boosting overall brand visibility and trust. What's Next LipLift launches Tuesday, and the brand will likely monitor consumer adoption and clinical feedback to gauge its trajectory. With industry estimates suggesting $5 million to $7 million in first-year sales, the product could become a significant contributor to the company’s growth. The expansion into seven Bloomingdale’s stores also sets the stage for potential further retail partnerships, though no specific plans have been announced. As the Contour Collection grows, questions remain about whether Dr. Diamond will extend the line to other facial areas, such as the neck or hands, which also show signs of aging. For now, the focus is on lips—and whether the product can replicate EyeLift’s success in a category that is notoriously difficult to treat topically.